Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials

Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.

(2017) L. G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

(2015) Cora N Sternberg et al.   LANCET ONCOLOGY

The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies

(2014) Brennan C Kahan et al.   Trials

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial

(2011) F. Cognetti et al.   ANNALS OF ONCOLOGY

A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners

(2011) D.J. Fisher et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status

(2011) Walter M. Stadler et al.   JOURNAL OF CLINICAL ONCOLOGY